2021: A Record Year for Life Science
This past year was a banner year for the life science industry. Amidst the ongoing pandemic, the life science industry experienced a surge in demand and access to both public and private capital. The year also included a number of legislative and tax incentive opportunities that benefit biotech and medical device companies.
There is no doubt that the industry experienced its fair share of turbulence as well. The effects of the great resignation have been felt across all industries and the cost of hiring and retaining talent are increasing. As we reflect on the challenges and opportunities of this past year, there are many strategies that can be carried into 2022.
Paul is a manager with CliftonLarsonAllen in the Life Science segment of the Manufacturing & Distribution industry group. He joined CliftonLarsonAllen in 2014 and provides assurance and tax services to privately-held clients in the manufacturing, distribution, retail, and technology industries which include companies with domestic and global operations. Additionally, Paul has worked with CliftonLarsonAllen's Transaction Advisory Group since 2015. Paul specializes in financial statement audits, reviews and compilations as well as business and individual tax services, buy side quality of earnings and sell side quality of earnings.
Comments are closed.